InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
Product | Citation | Year | Journal | Authors | Page |
---|---|---|---|---|---|
AddaVax™ | Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Viru... | 2022 | Vaccines (Basel). | Resch M.D. et al. | DOI: 10.3390/vaccines10121997 |
Human ACE2 expressing A549 Cells | Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Viru... | 2022 | Vaccines (Basel). | Resch M.D. et al. | DOI: 10.3390/vaccines10121997 |
G418 (Geneticin) | The Gal4-Type Transcription Factor Pro1 Integrates Inputs from Two Different ... | 2022 | J Fungi (Basel). | Palos-Fernández R. et al. | DOI: 10.3390/jof8121242 |
Primocin® | SCON-a Short Conditional intrON for conditional knockout with one-step zygote... | 2022 | Exp Mol Med. | Wu S.S. et al. | DOI: 10.1038/s12276-022-00891-0 |
FLA-ST (Standard or Ultrapure) | Lysosomal cathepsins act in concert with Gasdermin-D during NAIP/NLRC4-depend... | 2022 | Cell Death Dis. | Branco L.M. et al. | DOI: 10.1038/s41419-022-05476-3 |
Primocin® | Drug response profiles in patient-derived cancer cells across histological su... | 2022 | Br J Cancer | Murumägi A. et al. | DOI: 10.1038/s41416-022-02067-z |
Anti-CD20 (Rituximab biosimilar - IgG1 isotype) | AL008 Enhances Myeloid Antitumor Function by Inhibiting SIRPα Signaling and A... | 2022 | J Immunol. | Yang J. et al. | DOI: 10.4049/jimmunol.2200157 |
Zeocin® | Impact of latency-reversing agents on human macrophage physiology. | 2022 | Immun Inflamm Dis. | Hany L. et al. | DOI: 10.1002/iid3.590 |
TNF-α Reporter HEK 293 Cells | Impact of latency-reversing agents on human macrophage physiology. | 2022 | Immun Inflamm Dis. | Hany L. et al. | DOI: 10.1002/iid3.590 |
QUANTI-Blue™ | Impact of latency-reversing agents on human macrophage physiology. | 2022 | Immun Inflamm Dis. | Hany L. et al. | DOI: 10.1002/iid3.590 |
Puromycin | Impact of latency-reversing agents on human macrophage physiology. | 2022 | Immun Inflamm Dis. | Hany L. et al. | DOI: 10.1002/iid3.590 |
Primocin® | Neuromedin U secreted by colorectal cancer cells promotes a tumour-supporting... | 2022 | Cell Commun Signal | Przygodzka P. et al. | DOI: 10.1186/s12964-022-01003-1 |
PMA - Phorbol myristate acetate | Neuromedin U secreted by colorectal cancer cells promotes a tumour-supporting... | 2022 | Cell Commun Signal | Przygodzka P. et al. | DOI: 10.1186/s12964-022-01003-1 |
PlasmoTest™ - Mycoplasma Detection Kit | Neuromedin U secreted by colorectal cancer cells promotes a tumour-supporting... | 2022 | Cell Commun Signal | Przygodzka P. et al. | DOI: 10.1186/s12964-022-01003-1 |
Poly(I:C) HMW | Mitochondrial cristae architecture protects against mtDNA release and inflamm... | 2022 | Cell Rep. | He B. et al. | DOI: 10.1016/j.celrep.2022.111774 |
Blasticidin | Mitochondrial cristae architecture protects against mtDNA release and inflamm... | 2022 | Cell Rep. | He B. et al. | DOI: 10.1016/j.celrep.2022.111774 |
Puromycin | Mitochondrial cristae architecture protects against mtDNA release and inflamm... | 2022 | Cell Rep. | He B. et al. | DOI: 10.1016/j.celrep.2022.111774 |
R848 (Resiquimod) | miR-31-5p Regulates Type I Interferon by Targeting SLC15A4 in Plasmacytoid De... | 2022 | J Inflamm Res. | Li S. et al. | DOI: 10.2147/JIR.S383623 |
Alhydrogel® adjuvant 2% | Vaccination with a Zika virus envelope domain III protein induces neutralizin... | 2022 | Trop Med Health | Shin M. et al. | DOI: 10.1186/s41182-022-00485-6 |
G418 (Geneticin) | Cohesin and CTCF control the dynamics of chromosome folding. | 2022 | Nat Genet. | Mach P. et al. | DOI: 10.1038/s41588-022-01232-7 |